Patient Guide: A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 191 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06646276
Status: 🟢 Enrolling Now
Condition: Extensive-Stage Small Cell Lung Cancer
Phase: PHASE3

Where You Can Participate

This study is available at 191 locations across the country.

Top locations include:
  • • Daphne, Alabama
  • • Hot Springs, Arkansas
  • • Fort Myers, Florida
  • • And 188 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). - Join Clinical Trial NCTNCT06646276

How to Join This Clinical Trial - NCTNCT06646276

Learn how to participate in this PHASE3 trial studying an investigational therapy for Extensive-Stage Small Cell Lung Cancer. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Extensive-Stage Small Cell Lung Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Extensive-Stage Small Cell Lung Cancer
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06646276 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 191 locations. Find a study site near you:

Clinical Research Site

Daphne, Alabama 36526 - United States

Status: RECRUITING

Clinical Research Site

Hot Springs, Arkansas 71913 - United States

Status: COMPLETED

Clinical Research Site

Fort Myers, Florida 33901 - United States

Status: RECRUITING

Clinical Research Site

Orange City, Florida 32763 - United States

Status: RECRUITING

Clinical Research Site

Saint Petersburg, Florida 33705 - United States

Status: RECRUITING

Clinical Research Site

Marietta, Georgia 30060 - United States

Status: RECRUITING

Clinical Research Site

Peoria, Illinois 61615 - United States

Status: RECRUITING

Clinical Research Site

Minneapolis, Minnesota 55407 - United States

Status: WITHDRAWN

Clinical Research Site

Albuquerque, New Mexico 87106 - United States

Status: RECRUITING

Clinical Research Site

Durham, North Carolina 27710 - United States

Status: RECRUITING

And 181 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Extensive-Stage Small Cell Lung Cancer:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships